Shamburg News · 8-K filed Nov 13, 2026, 4:04 PM EST

TRex Bio Reports Third Quarter 2026 Financial Results and Business Highlights

TRXB · TRex Bio, Inc.

  • Earnings
  • Materiality: high

TRex Bio, Inc. reported a net loss of $13.2 million for the third quarter ended September 30, 2026, compared with $7.9 million in the prior-year quarter, with R&D expenses of $11.4 million. Cash, cash equivalents and marketable securities totaled $78.2 million as of September 30, 2026, excluding approximately $119.0 million in net IPO proceeds from the October 2026 offering. The company expects its resources to fund operations into the second half of 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-460588.

Written from the filing by Shamburg Markets. Figures are as reported by the company.